Tag: consortium

Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study [Gastrointestinal Cancer]

Conclusion
Combination chemotherapy with bevacizumab and erlotinib showed clinical activity with infrequent grade 3 and 4 adverse effects in patients with advanced biliary cancers. On the basis of preliminary molecular analysis, presence of a k-ras mutation may alter erlotinib efficacy. The combination of bevacizumab and erlotinib may be a therapeutic alternative in patients with advanced biliary cancer. (Source: Journal of Clinical Oncology)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Source: MedWorm: Oral Cancer

  • Share/Bookmark

Tags: , , , , , , , , , , , , , , , ,

Posted in Treatment | No Comments »

Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium

Conclusions Sexual behaviours are associated with cancer risk at the head and neck cancer subsites that have previously been associated with HPV infection. (Source: International Journal of Epidemiology) Source: MedWorm: Oral Cancer

  • Share/Bookmark

Tags: , , , , , , , , , , , ,

Posted in Treatment | No Comments »

Powered by WordPress

Blossom Theme by RoseCityGardens.com